{
    "clinical_study": {
        "@rank": "23177", 
        "arm_group": {
            "arm_group_label": "Rasagiline", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to fulfil regulatory requirements for registration of a new\n      chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease\n      (PD) in Europe and the US. Rasagiline is safe and well tolerated in healthy subjects, and\n      the efficacy and safety has been demonstrated in placebo- and active comparator-controlled\n      phase III studies."
        }, 
        "brief_title": "Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject is a Chinese man or woman\n\n          -  The subject is, in the opinion of the investigator, generally healthy\n\n          -  If female, the subject must have a negative pregnancy test at screening and baseline,\n             and agree not to try to become pregnant from Screening until after the Follow-up\n             Visit\n\n        Exclusion Criteria:\n\n          -  The subject is, in the opinion of the investigator, unlikely to comply with the\n             clinical study protocol or is unsuitable for any other reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652313", 
            "org_study_id": "13496A"
        }, 
        "intervention": {
            "arm_group_label": "Rasagiline", 
            "description": "1 mg/day, tablets for 7 days, orally", 
            "intervention_name": "Rasagiline", 
            "intervention_type": "Drug", 
            "other_name": "Lu 00-773; Azilect\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Rasagiline"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 25, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "CN001"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women", 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetic (PK) AUC determination of rasagiline and its metabolite 1-aminoindan (1-AI)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "PK Cmax determination of rasagiline and its metabolite 1-aminoindan (1-AI)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}